Other languages Clene Inc.

Equities

CLNN

US1856341029

Market Closed - Nasdaq Other stock markets 04:00:00 2024-05-31 pm EDT			5-day change	1st Jan Change
0.329 ^USD	-3.58%		-6.27%	+10.92%

May. 08	Earnings Flash (CLNN) CLENE Reports Q1 Revenue $73M	MT
May. 08	Clene Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	CI

Other languages

Unlock all the news: Be the first to know and act before the market!

100% Free Registration

Clene Provides Update on Its NIH-Funded Expanded Access Program for CNM-Au8® in ALS (ACT-EAP)	May. 28
Clene to Present at Upcoming May Conferences	May. 14
Earnings Flash (CLNN) CLENE Reports Q1 Revenue $73M	May. 08
Clene Reports First Quarter 2024 Financial Results and Recent Operating Highlights	May. 08
Clene Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	May. 08
IBN Announces From Lab to Launch Podcast Featuring Clene Inc. CEO Rob Etherington	May. 01
Clene : 2023 Annual Report to Stockholders	Apr. 17
Evidence for Clene’s CNM-Au8® as a Treatment for Repair and Remyelination in Multiple Sclerosis Presented in the Emerging Science Session at the 2024 American Academy of Neurology Annual Meeting	Apr. 16
Clene Inc. and Clene Nanomedicine, Inc. Presented the Phase 2 VISIONARY-MS Long term Extension Study Results at the 2024 American Academy of Neurology Annual Meeting in Denver	Apr. 16
IBN Announces First in Human Podcast Featuring Clene Inc. CEO Rob Etherington	Mar. 19
Clene Announces Peer-Reviewed Publication Characterizing the Protein Corona of the Investigational Neurodegenerative Disease Drug, CNM-Au8®	Mar. 15
Clene Inc. Announces Peer-Reviewed Publication Characterizing the Protein Corona of the Investigational Neurodegenerative Disease Drug, CNM-Au8	Mar. 15
Clene Reports Full Year 2023 Financial Results and Recent Operating Highlights	Mar. 13
Clene Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	Mar. 13
North American Morning Briefing : Stock Futures -2-	Mar. 11
Clene to Present at the 36th Annual ROTH Conference	Mar. 07
Clene Presents Clinical Results of CNM-Au8® 30mg Treatment From Visionary-MS Trial Long-Term Extension at Annual ACTRIMS Forum 2024	Feb. 29
Clene Reports Significant Survival Benefit With CNM-Au8® Treatment in ALS EAP Compassionate Use Programs	Feb. 22
Clene Reports Significant Survival Benefit with Cnm-Au8® Treatment in Als Eap Compassionate Use Programs	Feb. 22
Clene Inc. announces positive results from CNM-Au8 results from MS trial	Feb. 05

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Other languages Clene Inc.

Equities

CLNN

US1856341029

Other languages

Filters